English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

A large number of prostate cancer (PCa) patients receive treatment without significant benefits, strengthening the need for accurate prognosis, which can be supported by the study of miRNAs.  In silico  specificity analysis was performed for the identification of miRNAs able to regulate  KLK2  and  KLK4  expression. Total RNA was extracted from prostate tissues obtained from PCa and benign prostate hyperplasia patients. Thereafter, RNA was polyadenylated and reverse transcribed to cDNA, which was used for qPCR analysis. miR-378 was predicted to target both  KLK2  and  KLK4  and downregulated levels detected in PCa patients ( p =0.050). The reduction of miR-378 was correlated with higher Gleason score ( p =0.018), larger diameter tumors ( p =0.034), and elevated serum PSA ( p =0.006). Regarding prognosis, miR-378 was able to improve risk stratification according to Gleason score or tumor stage, while higher risk to recur highlighted for the patients expressing lower miR-378 levels. Finally, the loss of miR-378 was able to predict the short-term relapse of ‘high’- and ‘very high’-recurrence-risk patients, independent of Gleason score, tumor stage, PSA, and age as indicated by Kaplan-Meier survival curves ( p =0.030) and multivariate Cox regression analysis ( p =0.018). In conclusion, loss of miR-378 expression increases the risk for PCa progression and relapse, despite active treatment.

biological chemistry

Loss of miR-378 in prostate cancer, a common regulator of  KLK2  and  KLK4 , correlates with aggressive disease phenotype and predicts the short-term relapse of the patients